A headset before chemotherapy, and the benefit grows by the second cycle

Design

assessor-blinded, parallel-group randomised controlled trial at a single children's hospital, five assessment points across two chemotherapy cycles

Population

128 children aged 6 to 12 with cancer undergoing their first chemotherapy, mean age 9.02 years

Primary outcome

anxiety, anticipatory nausea and vomiting, and chemotherapy-induced nausea and vomiting

Effect

anxiety time-by-group interaction d = -0.67 (before first cycle) rising to -1.48 (after second), all P < 0.001; fewer episodes of anticipatory nausea (P < 0.001) and CINV (P = 0.03)

This assessor-blinded randomised trial enrolled 128 children aged 6 to 12 starting their first chemotherapy at a children's hospital, and gave the intervention group immersive virtual reality around treatment. Outcomes were measured at baseline, before and after the first cycle, and before and after the second.

Anxiety fell further in the virtual reality group at every point, and the gap widened: standardised effect sizes ran from -0.67 before the first chemotherapy to -0.87 after it, -0.91 before the second and -1.48 after it (all P < 0.001). The intervention also reduced anticipatory nausea before the second cycle, chemotherapy-induced nausea and vomiting after it, and vomiting after both.

The widening effect is the interesting part, and it fits the mechanism. Anticipatory nausea is a learned response — the child who was frightened and sick the first time arrives expecting to be sick the second. An intervention applied from the first cycle is intervening before that learning is laid down, which is why starting it at cycle four in a child who already dreads the ward would not be the same experiment. The trial was single-centre and could not blind participants, so expectation effects on a subjective outcome like anxiety are unavoidable; the vomiting counts are harder to explain that way. This is a low-risk, cheap addition worth trialling from the first cycle rather than offered as rescue later.

• Offer it from the first cycle if at all — the mechanism is preventing anticipatory nausea being learned
• Do not treat it as a substitute for antiemetic prophylaxis
• Screen for motion sickness, seizure history and recent eye surgery before fitting a headset
• Record anticipatory symptoms separately from treatment-induced ones; they respond differently
• A shared departmental headset with cleanable covers is enough — the trial used no bespoke platform

The statistics, in plain English

Cohen's d expresses a difference in standard deviations: 0.67 is a medium effect and 1.48 a large one, so the intervention's advantage roughly doubled across two cycles. Participants could not be blinded to wearing a headset, which inflates effects on self-reported anxiety more than on counted vomiting episodes — the convergence of both is what makes the result persuasive. With 128 children at one centre, the trial can show that the effect exists but not how well it transfers to a ward with different staffing, or to children outside the 6-to-12 age band.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.